Siddharth Mittal, CEO & MD, Biocon, On Q4 Earnings, Pharma Market & Plans For Overseas Markets

In Q4FY24, our Total Consolidated Revenue grew by 1% year-on-year (YoY) to Rs 3,966 crore. Core EBITDA reached Rs 1,176 crore, maintaining core operating margins at 30%. Net R&D investments were Rs 246 crore, accounting for 8% of revenue excluding Syngene. The quarter's EBITDA was Rs 964 crore, representing a 24% EBITDA margin. Profit Before Tax and exceptional items stood at Rs 328 crore. Net Profit before exceptional items was Rs 144 crore, with a reported Net Profit of Rs 136 crore. Siddharth Mittal, CEO & MD, Biocon speaks to Business Today TV's Sakshi Batra on Q4 earnings, Phrama sector and growth plans for FY25 and expansion plans for FY25.